Title: CardioVascular BioTherapeutics, Inc.
Description: Cardio Vascular Bio Therapeutics - CVBT is a biopharmaceutical company established to commercialize the breakthrough therapy developed by Dr. Thomas-Joseph Stegmann to treat coronary artery disease with a process known as angiogenesis. The treatment cons
Keywords:Angiogenesis, ACORD, ACORD clinical trial, ACORD clinical trials, ACORD Phase II trial, CVBT Clinical Trial, CVBT ACORD Trial, ACORD Heart Trial, New Vessel Growth, Human Growth Factors, Coronary Heart Disease, Coronary Artery Disease, Adjunct Bypass Surgery, Atherosclerosis, Peripheral Artery Disease, Peripheral Vascular Disease, Stroke, Wound Healing, Nerve Regeneration, Regenerative Medicine, No Option Heart Patient, Diabetes, mellitus, Diabetic Vascular Disease, Ischemia,
... (View More)
Vascular Disease, Protein Drug, Protein Drug Candidate, Protein Drug Therapy, Neoangiogenesis, Fibroblast Growth Factor, FGF, Heart Disease, Grow Blood vessels, Biopharmaceutical, Biotech, Biotechnology, Heart disease, Angina cure, Regenerate tissue, Emerging Biotech growth company, Myocardial revascularization, Medical applications, Disease treatment, Cardiology, Medical research, Protein Growth Factor, Gene therapy, Thomas Stegmann, Daniel Montano, Blood vessel blockage, Cure coronary heart disease(View Less)
0%) - 
+
